111 related articles for article (PubMed ID: 29899684)
1. Does Sevelamer Hydrochloride (Renagel) Influence 25(Oh)D3 and 1,25(Oh)2D3 Level in Haemodialysis Patients?
Strózecki P; Ostrowski J; Majczynska I; Sulikowska B; Odrowaz-Sypniewska G; Stefanska A; Manitius J
EJIFCC; 2005 Dec; 16(4):100-102. PubMed ID: 29899684
[No Abstract] [Full Text] [Related]
2. Sevelamer hydrochloride (Renagel), a non-calcaemic phosphate binder, arrests parathyroid gland hyperplasia in rats with progressive chronic renal insufficiency.
Nagano N; Miyata S; Obana S; Ozai M; Kobayashi N; Fukushima N; Burke SK; Wada M
Nephrol Dial Transplant; 2001 Sep; 16(9):1870-8. PubMed ID: 11522872
[TBL] [Abstract][Full Text] [Related]
3. Renal mineral handling in normal rats treated with sevelamer hydrochloride (Renagel), a noncalcemic phosphate binder.
Nagano N; Miyata S; Obana S; Eto N; Fukushima N; Burke SK; Wada M
Nephron; 2001 Nov; 89(3):321-8. PubMed ID: 11598397
[TBL] [Abstract][Full Text] [Related]
4. Determination of the binding parameter constants of Renagel capsules and tablets utilizing the Langmuir approximation at various pH by ion chromatography.
Swearingen RA; Chen X; Petersen JS; Riley KS; Wang D; Zhorov E
J Pharm Biomed Anal; 2002 Jun; 29(1-2):195-201. PubMed ID: 12062678
[TBL] [Abstract][Full Text] [Related]
5. Hospitalization risks between Renagel phosphate binder treated and non-Renagel treated patients.
Collins AJ; St Peter WL; Dalleska FW; Ebben JP; Ma JZ
Clin Nephrol; 2000 Oct; 54(4):334-41. PubMed ID: 11076110
[TBL] [Abstract][Full Text] [Related]
6. RenaGel efficacy in severe secondary hyperparathyroidism.
Castro R; Herman A; Ferreira C; Travassos F; Nunes-Azevedo J; Oliveira M
Nefrologia; 2002; 22(5):448-55. PubMed ID: 12497746
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients.
Wilkes BM; Reiner D; Kern M; Burke S
Clin Nephrol; 1998 Dec; 50(6):381-6. PubMed ID: 9877112
[TBL] [Abstract][Full Text] [Related]
8. Effects of phosphonoformic acid and renagel on renal type IIa sodium-dependent phosphate cotransporter mRNA expression in hyperphosphatemia rats.
Zeng M; Wang X; Wang X; Zhao X
Ren Fail; 2012; 34(3):358-63. PubMed ID: 22260362
[TBL] [Abstract][Full Text] [Related]
9. Renagel: reducing serum phosphorus in haemodialysis patients.
Burke SK
Hosp Med; 2000 Sep; 61(9):622-7. PubMed ID: 11048603
[TBL] [Abstract][Full Text] [Related]
10. Determination of the binding parameter constants of Renagel capsules and tablets at pH 7 by high performance capillary electrophoresis.
Swearingen RA; Zhorov E; Cohen A; Sybertz T; Barry EF
J Pharm Biomed Anal; 2004 Jun; 35(4):753-60. PubMed ID: 15193719
[TBL] [Abstract][Full Text] [Related]
11. Comparison between 1alpha(OH)D3 and 1,25(OH)2D3 on the suppression of plasma PTH levels in uremic patients, evaluated by the 'whole' and 'intact' PTH assays.
Brandi L; Egfjord M; Olgaard K
Nephron Clin Pract; 2005; 99(4):c128-37. PubMed ID: 15722644
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients.
Chertow GM; Dillon M; Burke SK; Steg M; Bleyer AJ; Garrett BN; Domoto DT; Wilkes BM; Wombolt DG; Slatopolsky E
Clin Nephrol; 1999 Jan; 51(1):18-26. PubMed ID: 9988142
[TBL] [Abstract][Full Text] [Related]
13. Influence of dietary vitamin D3 on the circulating concentration of its active metabolites in the chick and rat.
Hughes MR; Baylink DJ; Gonnerman WA; Toverud SU; Ramp WK; Haussler MR
Endocrinology; 1977 Mar; 100(3):799-806. PubMed ID: 233823
[TBL] [Abstract][Full Text] [Related]
14. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure.
Chertow GM; Burke SK; Lazarus JM; Stenzel KH; Wombolt D; Goldberg D; Bonventre JV; Slatopolsky E
Am J Kidney Dis; 1997 Jan; 29(1):66-71. PubMed ID: 9002531
[TBL] [Abstract][Full Text] [Related]
15. Intravenous 1,25(OH)2 vitamin D3 therapy in haemodialysis patients: evaluation of direct and calcium-mediated short-term effects on serum parathyroid hormone concentration.
Probst W; Fischer JA; Binswanger U
Nephrol Dial Transplant; 1990; 5(6):457-60. PubMed ID: 2122324
[TBL] [Abstract][Full Text] [Related]
16. Sevelamer hydrochloride (Renagel), a nonabsorbed phosphate-binding polymer, does not interfere with digoxin or warfarin pharmacokinetics.
Burke S; Amin N; Incerti C; Plone M; Watson N
J Clin Pharmacol; 2001 Feb; 41(2):193-8. PubMed ID: 11210401
[TBL] [Abstract][Full Text] [Related]
17. Apparent nonnuclear regulation of intestinal phosphate transport: effects of 1,25-dihydroxyvitamin D3,24,25-dihydroxyvitamin D3, and 25-hydroxyvitamin D3.
Nemere I
Endocrinology; 1996 Jun; 137(6):2254-61. PubMed ID: 8641173
[TBL] [Abstract][Full Text] [Related]
18. Influence of vitamin D3 metabolites on the production of interleukins 1,2 and 3.
Hodler B; Evêquoz V; Trechsel U; Fleisch H; Stadler B
Immunobiology; 1985 Nov; 170(4):256-69. PubMed ID: 3002965
[TBL] [Abstract][Full Text] [Related]
19. Vitamin D and systemic cancer: is this relevant to malignant melanoma?
Osborne JE; Hutchinson PE
Br J Dermatol; 2002 Aug; 147(2):197-213. PubMed ID: 12174089
[TBL] [Abstract][Full Text] [Related]
20. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
